2503, 2014

VLP Therapeutics Appoints Dr. Ryuji Ueno as Chair and Chief Medical Officer


VLP Therapeutics, Inc. ("VLP"), a Rockville-based biotechnology company focusing on the research and development of next generation antibody agents and therapeutic as well as preventive vaccines based upon a novel and proprietary i-αVLP technology (which stands for "inserted alpha virus like particle"), today announced that Ryuji Ueno, M.D., Ph.D., Ph.D., Co-Founder and former Chair, Chief Executive Officer and Chief Scientific Officer of Sucampo Pharmaceuticals, Inc. (Nasdaq: SCMP) ("Sucampo") will join VLP as Chair and Chief Medical Officer, effective today.